Posts Tagged ‘BLTI’

BIOLASE Technology, Inc. (BLTI) shares spike on bottom line

Wednesday, August 10th, 2011

BIOLASE Technology, Inc. (Nasdaq: BLTI) shares leaped 19.1% to $3.31, after reporting quarterly net revenue of $12.1 million, up 105% from $5.9 million in the same quarter for 2010. Volume for the stock was more than 717,000, already surpassing a daily average of around 636,000.

A news release issued August 10 also noted that Q2 GAAP loss was $753,000, or $0.03 per share, with Q2 Non-GAAP profits around $6,000, or $0.00 per Share. This was the third consecutive quarter of Non-GAAP profit, first time since the second quarter of 2004.

The release also said the percentage of net revenue in this year’s second quarter from the U.S. and international markets totaled approximately 71% and 29%, respectively, as compared to approximately 60% and 40% of net revenue in the prior-year comparable period.

Federico Pignatelli, Chairman and CEO, was quoted in the same release as saying, “The rate of revenue growth and operational progress at the Company continued to accelerate in the second quarter and our momentum going into the second half of the year is strong. Sales activities across our laser product platforms remained very active — especially in the case of the Waterlase iPlus, which we believe will become the most successful all-tissue dental laser in history. In addition, we are now taking orders and will soon be shipping the first units from our new BIOLASE DaVinci Imaging™ product line.”

BIOLASE Technology, Inc., the world’s leading dental laser company, based in Irvine, California, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine.

BioLase Technology, Inc. (BLTI) – Buzz Stock of the Day

Thursday, January 20th, 2011

Shares of dental laser manufacturer and distributor, BioLase Technology, Inc. (Nasdaq: BLTI) soared as much as 89 percent from Wednesday’s closing price in morning trading on Thursday after the company announced that it expects to report fourth quarter net revenue ranging between $9.5 million and $10 million with positive net income excluding non-cash stock option expense.

Sales to Henry Schein, Inc. (Nasdaq: HSIC), one of the BioLase’s major distributors, accounted for approximately 20 percent of the revenue in Q4.

BioLase shares opened at $1.96 on Thursday,and reached a new 52-week high of $3.17.

The Irvine-based company also issued annual revenue guidance for 2011 ranging from $55 million to $60 million, about 120 percent to 140 percent over 2010. Analysts on average are expecting  revenue of $40.4 million. Net revenue for the first quarter ended March 31, 2011, traditionally the lowest quarter of the year, is expected to range between $8.75 million to $9.25 million, up from $4.4 million in the first quarter of 2010, with positive net income.

“We foresee a very promising 2011 with revenue and earnings growth on a quarterly basis,” said BioLase’s Chairman and CEO Federico Pignatelli in a statement. “”Following a restricted marketplace brought on by the recession and constricted credit, the dental high tech capital equipment market has now shown strong signs of a turnaround and there is reason to believe that it is poised for substantial growth, with the laser dental market at the high end of the spectrum of choices.”

BioLase’s Board of Directors also approved a stock dividend of one percent effective January 19, 2011, and payable on March 31, 2011, to shareholders of record on March 15, 2011. In addition, the Board adopted a four percent annual stock dividend policy.

BioLase Technology designs, manufactures and markets proprietary dental laser systems that allow dentists, oral surgeons and other specialists to perform a broad range of common dental procedures, including cosmetic applications.

Shares of BLTI are up about 93 percent over the past three months.

BLTI climbs, C steady, MNKD manhandled

Thursday, January 20th, 2011

BioLase Technology Inc. (Nasdaq: BLTI) vaulted 80.2 percent in price Thursday to $3.01. Volume of 1,723,791 shares overwhelmed its full-day average of 46,341. Biolase said today it expects to post a profit after four quarters of loss, sending the dental laser company’s shares up 68 percent to a year-high.

Citigroup Inc. (NYSE: C) dealt in 228,816,253 shares, inching toward its full-day average of 551,205,000. Share prices edged higher 0.1 percent to $4.76.

MannKind Corp. (Nasdaq: MNKD) shares tumbled 42.4% to $5.27. Volume was 12,079,531, or four times its full-day average, after the biotechnology company failed to obtain regulatory approval to market its insulin inhaler.

CHTP jumps, CSCO trades wide, BLTI tumbles

Monday, December 20th, 2010

Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) zoomed higher 19.13 percent in price Monday to $7.16. Volume of 3,471,695 shares better than tripled its full-day average. The Charlotte-based CHTP announced it has completed a pre-NDA assessment with the FDA and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension.

Cisco Systems Inc. (Nasdaq: CSCO) was busy early Monday afternoon, trading in 26,465,845 shares, making headway against its daily average of 71,898,900. Share prices for CSCO crept ahead 0.69 percent to $19.68.

BioLase Technology Inc. (Nasdaq: BLTI) fell in price 11.05 percent Monday to $1.69, on volume of 64,212 shares, approaching its full-day average of 78,005. BLTI, based in Irvine, Calif., is the world’s leading dental laser manufacturer and distributor.